Cargando…

Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study

Introduction. Cardiovascular risk factors, pre-existing comorbidities, molecular factors, and the direct effects of second- and third-generation BCR-ABL1 tyrosine kinase inhibitors on the vascular endothelium contribute to the progression of cardiovascular (CV) events, especially atherothrombotic co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varga, Andreea, Tilea, Ioan, Petra, Dorina Nastasia, Tilinca, Mariana-Cornelia, Gliga, Mirela Liana, Demian, Smaranda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600382/ https://www.ncbi.nlm.nih.gov/pubmed/33053860 http://dx.doi.org/10.3390/jcm9103269

Ejemplares similares

Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center
por: Tilea, Ioan, et al.
Publicado: (2021)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review)
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

The Pathophysiology and Management of Diabetic Ketoacidosis in COVID-19 Patients: a Literature Review
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Treatment adherence among adult hypertensive patients: a cross-sectional retrospective study in primary care in Romania
por: Tilea, Ioan, et al.
Publicado: (2018)

Critical Care Management of Decompensated Right Heart Failure in Pulmonary Arterial Hypertension Patients – An Ongoing Approach
por: Tilea, Ioan, et al.
Publicado: (2021)

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges
por: Tilea, Ioan, et al.
Publicado: (2021)

The Gender Gap in Aortic Dissection: A Prospective Analysis of Risk and Outcomes
por: Banceu, Cosmin, et al.
Publicado: (2023)

TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia
por: Tripon, Florin, et al.
Publicado: (2021)

A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Right Heart Failure as an Atypical Presentation of Chronic Type a Aortic Dissection - Multimodality Imaging for Accurate Diagnosis and Treatment. A Case Report and Mini-review of Literature
por: Tilea, Ioan, et al.
Publicado: (2022)

Sweet’s Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML)
por: Guarneri, Claudio, et al.
Publicado: (2018)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
por: Allegra, Sarah, et al.
Publicado: (2023)

Case Report: Myelodysplastic syndrome- associated myeloid sarcoma: an unusual clinical presentation of a rare disease
por: Horvath, Emoke, et al.
Publicado: (2016)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia
por: Crisan, AM, et al.
Publicado: (2015)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Erythropoiesis in Murine Myeloid Leukaemia
por: Tanaka, T.
Publicado: (1970)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

A Case of Myeloid Leukæmia
por: Ghosal, J. N.
Publicado: (1931)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
por: Hanekamp, Diana, et al.
Publicado: (2020)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
por: Hewison, Ann, et al.
Publicado: (2020)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study
por: Fajardoa, Carlos J, et al.
Publicado: (2022)

Human leukaemia: recent tissue culture studies on the nature of myeloid leukaemia.
por: Metcalf, D.
Publicado: (1973)

IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia
por: Kuett, Alexander, et al.
Publicado: (2015)

Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients
por: Gliga, Smaranda, et al.
Publicado: (2021)

Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
por: Balakumaran, Janatani, et al.
Publicado: (2019)

Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
por: Gu, Ruixin, et al.
Publicado: (2022)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Targeting apoptosis in acute myeloid leukaemia
por: Cassier, Philippe A, et al.
Publicado: (2017)

Adhesion Deregulation in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ogqopih6p2rcvbnbtg3gvh12gb